Common Contracts
22 similar Underwriting Agreement contracts by Evolus, Inc., Independent Bank Group, Inc., Insys Therapeutics, Inc., others
RADIAN GROUP INC. (a Delaware corporation)Underwriting Agreement • March 4th, 2024 • Radian Group Inc • Surety insurance • New York
Radian Group Inc., a Delaware corporation (the “Company”), confirms its agreement with each of RBC Capital Markets, LLC and Goldman Sachs & Co. LLC and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 12 hereof), for whom RBC Capital Markets, LLC and Goldman Sachs & Co. LLC are acting as representatives (in such capacity, the “Representatives”), with respect to the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective principal amounts set forth in said Schedule A of $625,000,000 aggregate principal amount of the Company’s 6.200% Senior Notes due 2029 (the “Securities”). The Securities are to be issued pursuant to the provisions of a Senior Indenture, dated as of March 4, 2013 (the “Base Indenture”), as supplemented by the Eighth Supplemental Indenture, to be dated as of March 4, 2024 (the “Suppl
MOONLAKE IMMUNOTHERAPEUTICS (a Cayman Islands exempted company) 8,000,000 Ordinary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • June 29th, 2023 • MoonLake Immunotherapeutics • Pharmaceutical preparations • New York
MoonLake Immunotherapeutics, a Cayman Islands exempted company (the “Company”), confirms its agreement with SVB Securities LLC (“SVB Securities”) and Guggenheim Securities LLC (“Guggenheim”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for which SVB Securities and Guggenheim are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of Class A ordinary shares, par value $0.0001 per share, of the Company (“Ordinary Shares”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 1,200,000 additional Ordinary Shares. The aforesaid 8,000,000
bluebird bio, Inc. 20,000,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • January 19th, 2023 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances)
bluebird bio, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 20,000,000 shares (the “Firm Securities”) of common stock, par value $0.01 per share (“Stock”) and, at the election of the Underwriters, up to 3,000,000 additional shares of Stock (the “Optional Securities”) of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Securities”).
KKR REAL ESTATE FINANCE TRUST INC. 5,000,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: October 27, 2021Underwriting Agreement • November 1st, 2021 • KKR Real Estate Finance Trust Inc. • Real estate investment trusts • New York
F-STAR THERAPEUTICS, INC. (a Delaware corporation) 9,285,715 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • May 10th, 2021 • F-Star Therapeutics, Inc. • Pharmaceutical preparations • New York
F-star Therapeutics, Inc. (formerly known as Spring Bank Pharmaceuticals, Inc. (“Spring Bank”)), a Delaware corporation (the “Company,” with all references in this agreement to the “Company” also referring to Spring Bank prior to the date on which, pursuant to the terms of the Exchange Agreement, dated as of July 29, 2020, among Spring Bank, F-star Therapeutics Limited (“Former F-star”) and the sellers listed on Schedule I thereto, the shareholders of Former F-star exchanged all of their ordinary shares for shares of common stock of Spring Bank, resulting in Former F-star becoming a wholly-owned subsidiary of Spring Bank, and in connection therewith, Spring Bank changed its name to F-star Therapeutics, Inc.), confirms its agreement with SVB Leerink LLC (“SVB Leerink”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for which SVB Leeri
EVOLUS, INC. (a Delaware corporation) 9,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 26th, 2021 • Evolus, Inc. • Pharmaceutical preparations • New York
Evolus, Inc., a Delaware corporation (the “Company”), confirms its agreement with SVB Leerink LLC (“SVB Leerink”), Stifel, Nicolaus & Company, Incorporated (“Stifel”), Cantor Fitzgerald & Co. (“CF&Co.”), and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for which SVB Leerink, Stifel and CF&Co. are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of common stock, par value $0.00001 per share, of the Company (“Common Stock”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 1,350,000 additional shares of Common Stock. The af
SeaSpine Holdings Corporation 6,800,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 8th, 2020 • SeaSpine Holdings Corp • Surgical & medical instruments & apparatus • New York
UNDERWRITING AGREEMENTUnderwriting Agreement • November 12th, 2019 • Evolus, Inc. • Pharmaceutical preparations • New York
Evolus, Inc., a Delaware corporation (the “Company”), confirms its agreement with SVB Leerink LLC (“SVB Leerink”), Stifel, Nicolaus & Company, Incorporated (“Stifel”), Cantor Fitzgerald & Co. (“CF&Co.”), and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for which SVB Leerink, Stifel and CF&Co. are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of common stock, par value $0.00001 per share, of the Company (“Common Stock”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 782,550 additional shares of Common Stock. The afor
RADIAN GROUP INC. (a Delaware corporation)Underwriting Agreement • June 18th, 2019 • Radian Group Inc • Surety insurance • New York
Radian Group Inc., a Delaware corporation (the “Company”), confirms its agreement with each of RBC Capital Markets, LLC, and Goldman Sachs & Co. LLC and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 12 hereof), for whom RBC Capital Markets, LLC, and Goldman Sachs & Co. LLC are acting as representatives (in such capacity, the “Representatives”), with respect to the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective principal amounts set forth in said Schedule A of $450,000,000 aggregate principal amount of the Company’s 4.875% Senior Notes due 2027 (the “Securities”). The Securities are to be issued pursuant to the provisions of a Senior Indenture, dated as of March 4, 2013 (the “Base Indenture”), as supplemented by the Sixth Supplemental Indenture, to be dated as of June 24, 2019 (the “Supp
SeaSpine Holdings Corporation 3,250,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 11th, 2018 • SeaSpine Holdings Corp • Surgical & medical instruments & apparatus • New York
CHESAPEAKE UTILITIES CORPORATION 835,207 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 28th, 2016 • Chesapeake Utilities Corp • Natural gas transmisison & distribution • New York
Independent Bank Group, Inc. 5.875% Subordinated Notes due August 1, 2024 Underwriting AgreementUnderwriting Agreement • June 23rd, 2016 • Independent Bank Group, Inc. • State commercial banks • New York
Independent Bank Group, Inc. 5.875% Subordinated Notes due August 1, 2024 Underwriting AgreementUnderwriting Agreement • July 18th, 2014 • Independent Bank Group, Inc. • State commercial banks • New York
RIVER VALLEY BANCORP (an Indiana corporation) [·] Shares of Common Stock (No Par Value Per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • June 13th, 2014 • River Valley Bancorp • Savings institution, federally chartered • New York
IMMUNOMEDICS, INC. 9,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • May 2nd, 2014 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
SUNDANCE ENERGY AUSTRALIA LIMITED AMERICAN DEPOSITARY SHARES REPRESENTING ORDINARY SHARES (NO PAR VALUE) UNDERWRITING AGREEMENTUnderwriting Agreement • February 20th, 2014 • Sundance Energy Australia LTD • Crude petroleum & natural gas • New York
ZOGENIX, INC. 26,666,667 Shares Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • November 6th, 2013 • Zogenix, Inc. • Pharmaceutical preparations • New York
Zogenix, Inc., a Delaware corporation (the “Company”), confirms its agreement with Stifel, Nicolaus & Company, Incorporated (“Stifel”), Leerink Swann LLC (“Leerink”) and each of the other Underwriters named in Schedule I hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Stifel and Leerink are acting as representatives (in such capacity, the “Representatives”), with respect to the issue and sale by the Company of 26,666,667 shares (the “Initial Securities”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of Initial Securities set forth in said Schedule I hereto, and with respect to the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of the 4,000,000 addi
BIOCRYST PHARMACEUTICALS, INC. 4,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • August 5th, 2013 • Biocryst Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
INSYS THERAPEUTICS, INC. Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 16th, 2013 • Insys Therapeutics, Inc. • Pharmaceutical preparations • New York
ZOGENIX, INC. 32,500,000 Units Consisting of One Share of Common Stock and A Warrant to Purchase 0.45 of a Share of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 24th, 2012 • Zogenix, Inc. • Pharmaceutical preparations • New York
Zogenix, Inc., a Delaware corporation (the “Company”), confirms its agreement with Stifel, Nicolaus & Company, Incorporated (“Stifel”), Wells Fargo Securities, LLC (“Wells Fargo”) and each of the other Underwriters named in Schedule I hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Stifel and Wells Fargo are acting as representatives (in such capacity, the “Representatives”), with respect to the issue and sale by the Company of 32,500,000 units (the “Initial Securities”), each unit consisting of (i) one share (each, a “Share”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and (ii) a warrant to purchase 0.45 of a share of Common Stock (each, a “Warrant”), and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of Initial Securities set forth in said Schedule I hereto, and with respect to the grant by the Co
HOME LOAN SERVICING SOLUTIONS, LTD. 13,333,333 Ordinary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • February 10th, 2012 • Home Loan Servicing Solutions, Ltd. • Mortgage bankers & loan correspondents • New York
INSYS THERAPEUTICS, INC. Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 15th, 2011 • Insys Therapeutics, Inc. • Pharmaceutical preparations • New York
